Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

AVB-101

- PMLiVE

Lilly and WHO Foundation partner to support global dementia action plan

The partnership will provide financial support and strengthen early detection and intervention efforts

- PMLiVE

Lilly launches global Alzheimer’s campaign with Julianne Moore

The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health

- PMLiVE

GSK to explore link between Shingrix and dementia risk in new UK research collaboration

More than 55 million people worldwide are currently living with the neurodegenerative disease

- PMLiVE

UK drug repurposing study identifies several potential dementia treatments

An estimated 982,000 people in the UK are currently living with the neurodegenerative disease

- PMLiVE

Eli Lilly shares positive results for modified titration of Alzheimer’s drug donanemab

The neurodegenerative disorder accounts for up to 75% of the 982,000 dementia cases in the UK

- PMLiVE

Astellas’ Vyloy approved by FDA as first-line gastric cancer combination treatment

Approximately 26,890 new cases of gastric cancer will be diagnosed in the US this year

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval

About 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE

Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn

Frontotemporal dementia accounts for less than one in 30 cases of the neurodegenerative disorder

- PMLiVE

Astellas’ Vyloy combination approved by EC as first-line gastric cancer treatment

Approximately 136,000 cases of the disease are diagnosed in Europe every year

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination granted EC approval

Bladder cancer is the fifth most commonly diagnosed cancer in Europe, with more than 165,000 annual cases

- PMLiVE

Lancet Commission report identifies two new modifiable dementia risk factors

The new risk factors identified are untreated vision loss and high low-density lipoprotein

- PMLiVE

Astellas’ zolbetuximab combination receives positive CHMP opinion for advanced gastric cancer

Gastric cancer is currently the sixth-most common cause of cancer-related mortality in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links